Claro Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Claro Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,275	Closed	-$221K	–	566
2026 Q1	$221K	Buy	+4,275	New	+$218K	0.03%	458

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Claro Advisors's SUPN Position: Q2 2026 in Review

Claro Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q2 2026, closing a stake of 4,275 shares — an estimated $221K sold.

Claro Advisors first reported a position in SUPN in Q1 2026 and held it in 1 quarter. The position peaked at $221K in Q1 2026. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

Claro Advisors reported no remaining Supernus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Claro Advisors sold 4,275 Supernus Pharmaceuticals shares in Q2 2026, an estimated $221K.
Claro Advisors first reported a position in Supernus Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Claro Advisors's Supernus Pharmaceuticals position peaked at $221K in Q1 2026.
334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Claro Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.